CDEK
← All drugs Report issue

adomeglivant

Small moleculeexperimental

Clinical trial activity

17 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2007 (NCT01606371)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1
Mol. weight
555.64 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • adomeglivant
  • adomeglivant
  • adomeglivant
  • ly2409021
  • ly2409021
  • ly-2409021
  • ly-2409021

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02944110N/AMay 1, 2016Eli Lilly, University of Copenhagen
NCT02669524N/AOct 1, 2015Eli Lilly, University of Copenhagen
NCT02385084Phase 1Mar 1, 2015Eli Lilly
NCT02217618Phase 1Aug 1, 2014Eli Lilly
NCT02111096Phase 2Apr 1, 2014Eli Lilly
NCT02091362Phase 2Mar 1, 2014Eli Lilly
NCT01929109Phase 1Aug 1, 2013Eli Lilly
NCT01836198Phase 1May 1, 2013Eli Lilly
NCT01640834Phase 1Jul 1, 2012Eli Lilly
NCT01588366Phase 1Apr 1, 2012Eli Lilly
NCT01460368Phase 1Oct 1, 2011Eli Lilly
NCT01354496Phase 1Apr 1, 2011Eli Lilly
NCT01241448Phase 2Jan 1, 2011Eli Lilly
NCT00871572Phase 2Mar 1, 2009Eli Lilly
NCT01606397Phase 1Mar 1, 2008Eli Lilly
NCT01606423Phase 1Nov 1, 2007Eli Lilly
NCT01606371Phase 1May 1, 2007Eli Lilly
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit171532007
University of CopenhagenAcademic/Hospital2212015
2 organizations
Page 1 / 1